Literature DB >> 19383824

Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma.

Sarah L Fishman1, Stephanie H Factor, Cinzia Balestrieri, Xiaofeng Fan, Adrian M Dibisceglie, Suresh M Desai, Gary Benson, Andrea D Branch.   

Abstract

PURPOSE: Hepatitis C virus (HCV) infection can promote the development of hepatocellular carcinoma (HCC). Published data implicate the HCV core gene in oncogenesis. We tested the hypothesis that core gene sequences from HCC patients differ from those of patients without cirrhosis/HCC. EXPERIMENTAL
DESIGN: Full-length HCV sequences from HCC patients and controls were obtained from the investigators and GenBank and compared with each other. A logistic regression model was developed to predict the HCC risk of individual point mutations and other sequence features. Mutations in partial sequences (bases 36-288) from HCC patients and controls were also analyzed. The first base of the AUG start codon was designated position 1.
RESULTS: A logistic regression model developed through analysis of full-length core gene sequences identified seven polymorphisms significantly associated with increased HCC risk (36G/C, 209A, 271U/C, 309A/C, 435A/C, 481A, and 546A/C) and an interaction term (for 209A-271U/C) that had an odds ratio <1.0. Three of these polymorphisms could be analyzed in the partial sequences. Two of them, 36G/C and 209A, were again associated with increased HCC risk, but 271U/C was not. The odds ratio of 209A-271U/C was not significant.
CONCLUSIONS: HCV core genes from patients with and without HCC differ at several positions. Of interest, 209A has been associated with IFN resistance and HCC in previous studies. Our findings suggest that HCV core gene sequence data might provide useful information about HCC risk. Prospective investigation is needed to establish the temporal relationship between appearance of the viral mutations and development of HCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383824      PMCID: PMC3142862          DOI: 10.1158/1078-0432.CCR-08-2418

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  41 in total

1.  A transgenic mouse model of steatosis and hepatocellular carcinoma associated with chronic hepatitis C virus infection in humans.

Authors:  S M Lemon; H Lerat; S A Weinman; M Honda
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

2.  Characteristics of hepatitis C viral genome associated with disease progression.

Authors:  K Nagayama; M Kurosaki; N Enomoto; Y Miyasaka; F Marumo; C Sato
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

3.  Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.

Authors:  Norio Akuta; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

4.  Hepatitis C virus (HCV) genotype 1b sequences from fifteen patients with hepatocellular carcinoma: the 'progression score' revisited.

Authors:  K Takahashi; K Iwata; M Matsumoto; H Matsumoto; K Nakao; T Hatahara; Y Ohta; K Kanai; H Maruo; K Baba; M Hijikata; S Mishiro
Journal:  Hepatol Res       Date:  2001-06       Impact factor: 4.288

5.  Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus.

Authors:  Hervé Lerat; Masao Honda; Michael R Beard; Kim Loesch; Jiaren Sun; Yan Yang; Michiari Okuda; Rainer Gosert; Shu-Yuan Xiao; Steven A Weinman; Stanley M Lemon
Journal:  Gastroenterology       Date:  2002-02       Impact factor: 22.682

6.  Comparison of serum and liver hepatitis C virus quasispecies in HCV-related hepatocellular carcinoma.

Authors:  M S De Mitri; L Mele; C H Chen; A Piccinini; R Chianese; A D'Errico; A Alberti; E Pisi
Journal:  J Hepatol       Date:  1998-12       Impact factor: 25.083

7.  HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV.

Authors:  Hongxing Qin; Norah J Shire; Erica D Keenan; Susan D Rouster; M Elaine Eyster; James J Goedert; Margaret James Koziel; Kenneth E Sherman
Journal:  Blood       Date:  2004-09-16       Impact factor: 22.113

8.  Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells.

Authors:  D Sakamuro; T Furukawa; T Takegami
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

9.  Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth.

Authors:  A K Ghosh; R Steele; K Meyer; R Ray; R B Ray
Journal:  J Gen Virol       Date:  1999-05       Impact factor: 3.891

10.  Structural determinants that target the hepatitis C virus core protein to lipid droplets.

Authors:  Steeve Boulant; Roland Montserret; R Graham Hope; Maxime Ratinier; Paul Targett-Adams; Jean-Pierre Lavergne; Francois Penin; John McLauchlan
Journal:  J Biol Chem       Date:  2006-05-16       Impact factor: 5.157

View more
  28 in total

1.  Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91.

Authors:  Yusuke Funaoka; Naoya Sakamoto; Goki Suda; Yasuhiro Itsui; Mina Nakagawa; Sei Kakinuma; Takako Watanabe; Kako Mishima; Mayumi Ueyama; Izumi Onozuka; Sayuri Nitta; Akiko Kitazume; Kei Kiyohashi; Miyako Murakawa; Seishin Azuma; Kiichiro Tsuchiya; Mamoru Watanabe
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

2.  The Core/E1 domain of hepatitis C virus genotype 4a in Egypt does not contain viral mutations or strains specific for hepatocellular carcinoma.

Authors:  Xiaoan Zhang; Soo Hyung Ryu; Yanjuan Xu; Tamerl Elbaz; Abdel-Rahman N Zekri; Ashraf Omar Abdelaziz; Mohamed Abdel-Hamid; Valerie Thiers; Santiago F Elena; Xiaofeng Fan; Adrian M Di Bisceglie
Journal:  J Clin Virol       Date:  2011-09-17       Impact factor: 3.168

3.  Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA.

Authors:  Norio Akuta; Fumitaka Suzuki; Masahiro Kobayashi; Hitomi Sezaki; Yusuke Kawamura; Tetsuya Hosaka; Mariko Kobayashi; Satoshi Saitoh; Yoshiyuki Suzuki; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Clin Microbiol       Date:  2015-07-01       Impact factor: 5.948

Review 4.  Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma.

Authors:  Virginia Sedeno-Monge; Veronica Vallejo-Ruiz; Francisca Sosa-Jurado; Gerardo Santos-Lopez
Journal:  J Biosci       Date:  2017-09       Impact factor: 1.826

5.  Treatment of hepatitis C infections with interferon: a historical perspective.

Authors:  Robert M Friedman; Sara Contente
Journal:  Hepat Res Treat       Date:  2010-09-06

Review 6.  Production and pathogenicity of hepatitis C virus core gene products.

Authors:  Hui-Chun Li; Hsin-Chieh Ma; Chee-Hing Yang; Shih-Yen Lo
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

7.  A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene.

Authors:  Ahmed El-Shamy; Francis J Eng; Erin H Doyle; Arielle L Klepper; Xiaochen Sun; Angelo Sangiovanni; Massimo Iavarone; Massimo Colombo; Robert E Schwartz; Yujin Hoshida; Andrea D Branch
Journal:  J Hepatol       Date:  2015-07-26       Impact factor: 25.083

Review 8.  Hepatocarcinogenesis associated with hepatitis B, delta and C viruses.

Authors:  Elham Shirvani-Dastgerdi; Robert E Schwartz; Alexander Ploss
Journal:  Curr Opin Virol       Date:  2016-08-06       Impact factor: 7.090

9.  Subgenotyping and genetic variability of hepatitis C virus in Palestine.

Authors:  Sahar Rayan Da'as; Maysa Azzeh
Journal:  PLoS One       Date:  2019-10-07       Impact factor: 3.240

10.  Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules.

Authors:  Julio A Gutierrez; Robert G Gish
Journal:  Transl Cancer Res       Date:  2013-12       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.